Walgreens Boots Alliance (WBA) shareholders are seeing their shares converted into a fixed cash payment of $ 11.45 $ 1 1 . 4 5 per share following the acquisition by Sycamore Partners, which was completed on August 28, 2025. Trading on the Nasdaq ceased on that date. Shareholders also received one non-transferable right to potentially receive up to an additional $ 3.00 $ 3 . 0 0 per share based on the future sale of VillageMD assets.
Sycamore Partners completed its acquisition of Walgreens (WBA) on August 28, 2025. Shareholders of WBA received $11.45 in cash for each share held at the close of trading on August 27, 2025. In addition, each shareholder was granted one non-transferable contingent value right (CVR) per share.
Following the closing of the transaction, Walgreens, The Boots Group, Shields Health Solutions, CareCentrix and VillageMD will operate as separate standalone companies. With the completion of the acquisition, WBA's common stock has ceased trading and will no longer be listed on the Nasdaq.
Walgreens stock will cease trading, and shareholders will receive $11.45 per share plus an additional up to $3 per share from the net proceeds of any potential future sales of VillageMD, the company said.
In addition to their cash consideration of $11.45 per WBA share, shareholders will receive one non-transferable right to receive up to an additional $3.00 in cash per WBA share from the net proceeds of the future monetization of the company's debt and equity interests in VillageMD, which includes the Village Medical, ...
Walgreens is being taken private
The deal is expected to close in the second half of 2025, with Walgreens shareholders getting $11.45 per share in cash. That's all that investors here can expect to receive if they buy Walgreens.
In August, Sycamore finalized its acquisition of Walgreens and appointed Mike Motz as the company's new CEO, with Wentworth remaining on the company's board. Sycamore will also split the company into five separate businesses: Walgreens, The Boots Group, Shields Health Solutions, CareCentrix, and VillageMD.
Walgreens (WBA) has been analyzed by 2 analysts, with a consensus rating of Sell. 0% of analysts recommend a Strong Buy, 0% recommend Buy, 50% suggest Holding, 0% advise Selling, and 50% predict a Strong Sell.
In some cases, the buyout may include a mix of cash and shares in the acquiring company, but most often, it's an all-cash deal. After the company is private, shares are not available for public trading, and any future ownership transfers occur privately, often with restrictions.
Walgreens is closing about 1,200 underperforming stores over three years, with roughly 500 slated for closure in their fiscal year 2025 (ending August 2025) as part of a cost-cutting "Footprint Optimization Program" due to financial pressures like decreased spending and competition. While a comprehensive list of all locations isn't released, specific closures occurred in cities like San Francisco, Macon, and Brooklyn, with many in May/June 2025, impacting states like California, Illinois, New Jersey, and North Carolina.
The transaction closed and WBA common stock ceased public trading. Guaranteed cash: Former public WBA holders received $11.45 in cash per share as the primary, immediate merger consideration.
Experts from across the healthcare industry agree that while Walgreens is currently in a grim financial situation, recovery is still possible. To make this happen, the company will have to relinquish its retail clinic dreams and focus more on making its core pharmacy business as efficient as it can.
Trading Ends: Shares of WBA stock will be delisted after trading closes on August 27, 2025. No Future Ownership: Once private, investors will no longer own stock or have a say in Walgreens' direction.
With the completion of the acquisition, WBA's common stock will no longer be listed on the Nasdaq Stock Market and WBA will become a private company. The total value of the transaction represents up to $23.7 billion.
Walgreens is being taken private
The deal is expected to close in the second half of 2025, with Walgreens shareholders getting $11.45 per share in cash. That's all that investors here can expect to receive if they buy Walgreens. That's the guaranteed upside limit.
You have the right to accept or reject the offer—as long as you know what the consequences are. Most people don't own enough shares to viably reject an offer, and therefore, won't have a big effect on how the company's management will react. In the end, you may even be forced to sell your shares.
Walgreens: Don't Expect The Dividend To Come Back Anytime Soon (NASDAQ:WBA) | Seeking Alpha.
As previously announced on March 6, 2025 , under the terms of the Merger Agreement, WBA shareholders will receive $11.45 per share in cash at closing, and one non-transferable Divested Asset Proceeds Right to receive up to an additional $3.00 in cash per share from the future monetization of WBA's debt and equity ...
Walgreens is closing about 1,200 underperforming stores over three years, with roughly 500 slated for closure in their fiscal year 2025 (ending August 2025) as part of a cost-cutting "Footprint Optimization Program" due to financial pressures like decreased spending and competition. While a comprehensive list of all locations isn't released, specific closures occurred in cities like San Francisco, Macon, and Brooklyn, with many in May/June 2025, impacting states like California, Illinois, New Jersey, and North Carolina.
Deal terms and valuation.
Shareholders received $11.45 per share in cash, totaling about $9.9 billion based on Walgreens' 865 million outstanding shares. They may also receive up to an additional $3 per share from the monetization of Walgreens' stake in VillageMD, bringing the total deal value up to $23.7 billion. 2.